JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraeber-Bodéré, F.
Right arrow Articles by Barbet, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraeber-Bodéré, F.
Right arrow Articles by Barbet, J.

Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial

Françoise Kraeber-Bodéré, MD, PhD1,2, Caroline Rousseau, MD1, Caroline Bodet-Milin, MD1, Ludovic Ferrer, MD1, Alain Faivre-Chauvet, PhD1,2, Loïc Campion, MD1, Jean-Philippe Vuillez, MD, PhD3, Anne Devillers, MD4, Chien-Hsing Chang, PhD5, David M. Goldenberg, ScD, MD5,6, Jean-François Chatal, MD, PhD1,2 and Jacques Barbet, PhD2

1 Nuclear Medicine Department, René Gauducheau Cancer Center, Nantes, France; 2 Oncology Research Department, INSERM U601, Nantes, France; 3 Nuclear Medicine Department, Michalon Hospital, Grenoble, France; 4 Nuclear Medicine Department, Eugène Marquis Cancer Center, Rennes, France; 5 IBC Pharmaceuticals, Inc., Morris Plains, New Jersey; and 6 Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey


Figure 1
View larger version (89K):

[in a new window]
  		FIGURE 1.  Images of SCLC patient showing thoracic and liver tumor involvement (arrows). (A) CT scan obtained before RIT shows multiple liver metastases. (B) Scintigraphy image (anterior view) obtained 7 d after injection of 131I-hapten shows targeting of thoracic and liver metastases.

 

Figure 2
View larger version (151K):

[in a new window]
  		FIGURE 2.  (A) Scintigraphy image (posterior view) obtained 7 d after injection of 131I-hapten shows high bone marrow uptake in MTC patient. (B) MR image of same patient indicates bone marrow metastases (arrows).

 

Figure 3
View larger version (116K):

[in a new window]
  		FIGURE 3.  Scintigraphy images (posterior view) illustrate distribution of 131I-hapten in MTC patient (A) and SCLC patient (B). Bone marrow uptake is higher in MTC patient.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.